This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The analysis and the parent study were funded by GlaxoSmithKline.
Yang S, et al. Healthcare Resource use in Patients with Severe Eosinophilic Asthma after the Initiation of Mepolizumab in Real-Life Settings: REALITI-A Study. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101382
About this article
Cite this article
Mepolizumab in severe eosinophilic asthma reduces healthcare use. PharmacoEcon Outcomes News 855, 22 (2020). https://doi.org/10.1007/s40274-020-6887-1